Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Polaryx Therapeutics, Inc. (PLYX)
Company Research
Source: GlobeNewswire
PARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as a Diamond honoree for Excellence in Pediatric Care. Polaryx was recognized for its innovative and scalable approach to treating lysosomal storage disorders (LSDs), a group of rare genetic diseases that cause progressive neurological decline and early mortality. Rather than developing therapies for individual conditions in isolation, the company is advancing a platform designed to target shared biological mechanisms, including lysosomal dysfunction and neuroinflammation, enabling a broader and more efficient approach to rare disease treatment. "While the limited existing therapies across these diseases has advanced care for lysosomal storage disorders, m
Show less
Read more
Impact Snapshot
Event Time:
PLYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLYX alerts
High impacting Polaryx Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLYX
News
- Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)GlobeNewswire
- Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy EventsGlobeNewswire
PLYX
Sec Filings
- 3/24/26 - Form 10-K
- 2/20/26 - Form 4
- 2/5/26 - Form SCHEDULE
- PLYX's page on the SEC website